ethyl (1-azabicyclo[2.2.2]octan-3-ylidene)cyanoacetate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 奎宁环
• 英文名称: ethyl (1-azabicyclo[2.2.2]octan-3-ylidene)cyanoacetate
• 英文别名: ethyl (2Z)-2-(1-azabicyclo[2.2.2]octan-3-ylidene)-2-cyanoacetate
• 化学式: C₁₂H₁₆N₂O₂
• 分子量: 220.271
• InChiKey: WRCZZMYKSMOYBK-ZHACJKMWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  53.3
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  ethyl (1-azabicyclo[2.2.2]octan-3-ylidene)cyanoacetate 在 palladium on charcoal 氢气 作用下， 以 乙醇 为溶剂， 生成 ethyl (1-azabicyclo[2.2.2]octan-3-yl)cyanoacetate
  参考文献：
  名称：

  Method of treating gastrointestinal motility disorders

  摘要：

  这项发明涉及一种治疗患有胃肠动力障碍的哺乳动物的新方法。

  公开号：

  US06265419B1
• 作为产物：
  描述：

  3-奎宁环酮盐酸盐 、 氰乙酸乙酯 在 三乙胺 作用下， 反应 2.0h， 生成 ethyl (1-azabicyclo[2.2.2]octan-3-ylidene)cyanoacetate
  参考文献：
  名称：

  3-(3-Alkylthio-1,2,5-thiadiazol-4-yl)-1-azabicycles. Structure—activity relationships for antinociception mediated by central muscarinic receptors

  摘要：

  3-(3-Alkylthio-1,2,5-thiadiazol-4-yl)-1-azabicycles (quinuclidines 7a-f; exo-1-azanorbornanes 8a-f and endo-1-azanorbornanes 9a-f) constitute a new class of muscarinic antinociceptive agents. A novel route for the synthesis of these compounds was constructed starting from the azabicyclic ketones. The compounds showed high affinity for muscarinic receptors as evidenced by inhibition of [H-3]oxotremorine-M ([H-3]Oxo-M) binding to brain homogenate (IC50 = 0.49-26 nM). In vivo, the compounds produced antinociception in the mouse grid shock test at doses well below those that produced salivation and tremor, with more than a 50-fold separation for some compounds. The enantiomers of 3-(3-butylthio-1,2,5-thiadiazol-4-yl)-1-azabicyclo[2.2.2]octane 7d exhibited little enantioselectivity with regard to either receptor affinity or analgesic activity.

  DOI：

  10.1016/0223-5234(96)89138-0

文献信息

• Certain 3-(1,2,5-oxa- or thiadiazol-4-yl)-1-azabicyclo [2.2.2]octanes
  申请人：Novo Nordisk A/S

  公开号：US05260314A1

  公开（公告）日：1993-11-09

  The present invention relates to therapeutically active piperidine compounds, a method of preparing the same and to pharmaceutical compositions comprising the compounds. The novel compounds are useful as stimulants of the cognitive function of the forebrain and hippocampus of mammals and especially in the treatment of Alzheimer's disease, severe painful conditions and glaucoma.

  本发明涉及治疗活性吡啶化合物，一种制备该化合物的方法以及包含该化合物的药物组合物。这些新颖的化合物可用作刺激哺乳动物前脑和海马的认知功能的兴奋剂，特别适用于治疗阿尔茨海默病、严重疼痛症状和青光眼。
• Heterocyclic compounds and their preparation and use
  申请人：Novo Nordisk A/S

  公开号：US05527813A1

  公开（公告）日：1996-06-18

  The present invention relates to therapeutically active azabicyclic compounds, a method of preparing the same and to pharmaceutical compositions comprising the compounds. The novel compounds are useful as stimulants of the cognitive function of the forebrain and hippocampus of mammals and especially in the treatment of Alzheimer's disease, severe painful conditions and glaucoma.

  本发明涉及治疗活性的杂环化合物，一种制备该化合物的方法以及包含该化合物的药物组合物。这些新颖的化合物可用作哺乳动物前脑和海马的认知功能刺激剂，特别适用于治疗阿尔茨海默病、严重疼痛症状和青光眼。
• Method of treating gastrointestinal motility disorders
  申请人：Novo Nordisk A/S

  公开号：US06265419B1

  公开（公告）日：2001-07-24

  The present invention relates to a novel method for treating a mammal suffering from gastrointestinal motility disorders.

  这项发明涉及一种治疗患有胃肠动力障碍的哺乳动物的新方法。
• 3-(3-Alkylthio-1,2,5-thiadiazol-4-yl)-1-azabicycles. Structure—activity relationships for antinociception mediated by central muscarinic receptors
  作者：PH Olesen、P Sauerberg、S Treppendahl、O Larsson、MJ Sheardown、PD Suzdak、CH Mitch、JS Ward、FP Bymaster、HE Shannon、MDB Swedberg

  DOI：10.1016/0223-5234(96)89138-0

  日期：1996.1

  3-(3-Alkylthio-1,2,5-thiadiazol-4-yl)-1-azabicycles (quinuclidines 7a-f; exo-1-azanorbornanes 8a-f and endo-1-azanorbornanes 9a-f) constitute a new class of muscarinic antinociceptive agents. A novel route for the synthesis of these compounds was constructed starting from the azabicyclic ketones. The compounds showed high affinity for muscarinic receptors as evidenced by inhibition of [H-3]oxotremorine-M ([H-3]Oxo-M) binding to brain homogenate (IC50 = 0.49-26 nM). In vivo, the compounds produced antinociception in the mouse grid shock test at doses well below those that produced salivation and tremor, with more than a 50-fold separation for some compounds. The enantiomers of 3-(3-butylthio-1,2,5-thiadiazol-4-yl)-1-azabicyclo[2.2.2]octane 7d exhibited little enantioselectivity with regard to either receptor affinity or analgesic activity.